Recent News
New Haven, Conn., August 08, 2019 – Kleo Pharmaceuticals, Inc. (Kleo), an immuno-oncology company developing next-generation synthetic bispecific compounds […] Read More...
Watch the Video to Learn More
Partnering Opportunities
Our technologies enable us to rapidly develop novel immunotherapies against targets of interest with potential partners.
Our Lead Programs
Kleo is rapidly advancing multiple candidates against a range of hematological and solid tumors
Partnering Opportunities
Our technologies enable us to rapidly develop novel immunotherapies against targets of interest with potential partners.
Our Lead Programs
Kleo is rapidly advancing multiple candidates against a range of hematological and solid tumors
Our Technologies
News
NEW HAVEN, Conn., June 18, 2019 /PRNewswire/ — Kleo Pharmaceuticals, Inc. (Kleo), an immuno-oncology company developing next-generation synthetic bispecific compounds designed to emulate or enhance […] Read More
NEW HAVEN, Conn., Feb. 26, 2019 /PRNewswire/ — Kleo Pharmaceuticals Inc., a unique immuno-oncology company developing next-generation bispecific compounds designed to emulate or […] Read More
Doug Manion, CEO of Kleo, talks about the company’s platform technology, why he thinks it will produce safer and more […] Read More
